CSF3 and neutropenia: Haematologic toxicities (Table 3) consisted primarily of grade 3–4 neutropenia in 83% (57% grade 4) of patients, despite the use of prophylactic G-CSF administration, whereas grade 3–4 thrombocytopenia was encountered in 9% (2% grade 4) of patients.